U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14ClO4.C5H14NO
Molecular Weight 421.914
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHOLINE FENOFIBRATE

SMILES

C[N+](C)(C)CCO.CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C([O-])=O

InChI

InChIKey=JWAZHODZSADEHB-UHFFFAOYSA-M
InChI=1S/C17H15ClO4.C5H14NO/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11;1-6(2,3)4-5-7/h3-10H,1-2H3,(H,20,21);7H,4-5H2,1-3H3/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C17H15ClO4
Molecular Weight 318.752
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H13NO
Molecular Weight 103.1628
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4500.0 nM [EC50]
1000.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FIBRICOR

Approved Use

FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (> 500 mg/dL); to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.37 μg/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
12 μg/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
124 μg × h/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
162.96 μg × h/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (3.3%)
Diarrhea (3.9%)
Dyspepsia (3.7%)
Nausea (4.3%)
Fatigue (2%)
Pain (3.5%)
Nasopharyngitis (3.5%)
Sinusitis (3.3%)
Upper respiratory tract infection (5.3%)
ALT increased (1.2%)
Arthralgia (3.9%)
Back pain (6.3%)
Muscle spasms (1.6%)
Myalgia (3.3%)
Pain in extremity (4.5%)
Dizziness (4.1%)
Headache (12.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
ALT increased 1.2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Muscle spasms 1.6%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Headache 12.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Fatigue 2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Constipation 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Myalgia 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Sinusitis 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Nasopharyngitis 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Pain 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Dyspepsia 3.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Arthralgia 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Diarrhea 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Dizziness 4.1%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Nausea 4.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Pain in extremity 4.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Upper respiratory tract infection 5.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Back pain 6.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
yes [IC50 2.2 uM]
yes [IC50 20 uM]
yes [IC50 282 uM]
yes [IC50 741 uM]
weak (co-administration study)
Comment: IC50 value from pre-incubation study; Coadministration with efavirenz (CYP2B6 substrate) resulted in AUC decrease of efavirenz by 12%
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
no
no
no
no
no
no
no
no
no
PubMed

PubMed

TitleDatePubMed
Optimal lipid modification: the rationale for combination therapy.
2005
Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
2005 Jul
Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells.
2005 Jul 1
Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.
2005 Jun
Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.
2005 Oct 3
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
2005 Sep 15
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
2005 Sep 15
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
2005 Sep 2
The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.
2006
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
2006 Dec
Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
2006 Jun
The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.
2006 May
Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.
2006 Nov 24
The transfer of a LC-UV method for the determination of fenofibrate and fenofibric acid in Lidoses: use of total error as decision criterion.
2006 Sep 11
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
2007
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.
2007 Aug
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
2007 Aug
LC-MS analysis and environmental risk of lipid regulators.
2007 Feb
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
2007 May
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
2008
Nanocrystal technology, drug delivery and clinical applications.
2008
Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems.
2008
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
2008 Aug 15
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
2008 Jul 10
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
2009
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
2009
Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.
2009
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.
2009
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.
2009 Apr
Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke.
2009 Apr 11
Advances in the medical treatment of diabetic retinopathy.
2009 Aug
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.
2009 Aug
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
2009 Dec
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
2009 Feb 15
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
2009 Jan
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
2009 Jan
Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.
2009 Jun
Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.
2009 Jun
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
2009 May
Fenofibric Acid (trilipix).
2009 May 4
Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
2009 Nov
In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.
2009 Nov
Myopathy with statin-fibrate combination therapy: clinical considerations.
2009 Sep
Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.
2009 Sep
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
2009 Sep 10
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
2010
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
2010
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
2010 Apr
Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation.
2010 Jan
Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.
2010 Jan
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:23:09 GMT 2023
Edited
by admin
on Sat Dec 16 16:23:09 GMT 2023
Record UNII
4BMH7IZT98
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHOLINE FENOFIBRATE
INN   MART.   ORANGE BOOK   USAN   WHO-DD  
USAN   INN  
Official Name English
ABT-335
Code English
Choline fenofibrate [WHO-DD]
Common Name English
FENOFIBRIC ACID CHOLINE SALT
Common Name English
FENOFIBRIC ACID CHOLINE SALT [MI]
Common Name English
CHOLINE FENOFIBRATE [USP-RS]
Common Name English
CHOLINE FENOFIBRATE [USAN]
Common Name English
choline fenofibrate [INN]
Common Name English
CHOLINE FENOFIBRATE [MART.]
Common Name English
TRILIPIX
Brand Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, SALT WITH 2-(4-(4- CHLOROBENZOYL)PHENOXY)-2-METHYLPROPANOIC ACID (1:1)
Common Name English
CHOLINE FENOFIBRATE [ORANGE BOOK]
Common Name English
2-HYDROXY-N,N,N-TRIMETHYLETHANAMINIUM 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2- METHYLPROPANOATE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC10AB11
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
WHO-ATC C10AB11
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
NCI_THESAURUS C98150
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT001885
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
INN
8868
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL981
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
DRUG CENTRAL
4505
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
EVMPD
SUB25725
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
FDA UNII
4BMH7IZT98
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
DAILYMED
4BMH7IZT98
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
MERCK INDEX
m5279
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID50234939
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
CAS
856676-23-8
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
RS_ITEM_NUM
1133558
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
SMS_ID
100000090599
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
RXCUI
1433887
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C75253
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
PUBCHEM
11350701
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
USAN
SS-76
Created by admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY